|Daybue (trofinetide)||Synthetic analogue of glycine-proline-glutamate||Treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.||FDA Greenlights Daybue for Treatment of Rett Syndrome|
|Verzenio (abemaciclib)||Kinase inhibitor||In combination with endocrine therapy (tamoxifen or an aromatase inhibitor), for the adjuvant treatment of adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer at high risk of recurrence.||Verzenio Drug Monograph|
|Tafinlar (dabrafenib) + Mekinist (trametinib)||Kinase inhibitors||Treatment of pediatric patients 1 year of age and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy.||Tafinlar + Mekinist Approved for Pediatric BRAF V600E Low-Grade Glioma|
|Zynyz (retifanlimab-dlwr)||Programmed death receptor-1-blocking antibody||Treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma.||Zynyz Approved for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma|
|Zavzpret (zavegepant)||Calcitonin gene-related peptide receptor antagonist||Treatment of migraine with or without aura in adults.||Zavzpret Nasal Spray Approved for Acute Treatment of Migraine|
|Joenja (leniolisib)||Selective PI3Kδ inhibitor||Treatment of activated phosphoinositide 3-kinase delta syndrome in patients 12 years of age and older.||Joenja Approved for Activated Phosphoinositide 3-Kinase Delta Syndrome|
|Rezzayo (rezafungin for injection)||Echinocandin antifungal||Treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.||FDA Approves Antifungal Rezzayo for Patients With Limited Treatment Options|
Please login or register first to view this content.